Skip to main content

Table 3 Tumor response at 6 months after the combination therapy

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Response

Patients, No. (%)

P value

CRAFITY-low (n = 25) *

CRAFITY-intermediate (n = 29) *

CRAFITY-high (n = 12) *

CR

7 (28.00%)

5 (17.24%)

1 (8.33%)

-

PR

13 (52.00%)

16 (55.17%)

5 (41.67%)

-

SD

4 (16.00%)

6 (20.69%)

4 (33.33%)

-

PD

1 (4.00%)

2 (6.90%)

2 (16.67%)

-

ORR

20 (80.00%)

21 (72.41%)

6 (50.00%)

0.165

DCR

24 (96.00%)

27 (93.10%)

10 (83.33%)

0.388

  1. * Data are presented as n (%). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us